TTK Healthcare
- Market cap
- ₹ 1,336 Cr.
- P/E
- 18.8x
- P/B
- 1.24x
- 52-week range
- 735 – 1,247
- ROE
- 6%
- ROCE
- 8%
- Dividend yield
- 1%
- Debt / equity
- 0.02
- Sector
- Diversified
- Industry
- Diversified
- Listed on
- NSE, BSE
About
TTK Healthcare Limited is an India-based company providing consumer and healthcare products. The Company's segments include Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods, and Others. The Animal Welfare segment offers products for veterinary use, including the brands Ossomin, Orcal-P, Epidosin, and others. The Consumer Products segment markets and distributes Woodward's Gripe Water, the EVA range of cosmetics, the Good Home range of scrubbers, air fresheners, and various other products. The Medical Devices segment includes the manufacturing and marketing of artificial heart valves, orthopedic implants, and others. The Protective Devices segment focuses on manufacturing and marketing male contraceptives and related products. The Foods segment involves the manufacturing and marketing of food products. Extruded products, such as papads, are offered under the brand name Fryums. The Others segment includes the printing and publishing of maps and atlases.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Diversified: 14 companies →TTK Healthcare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)18.8 against a typical 15: pricier than most peers (1st = cheapest).9th of 14
- Sales growth+14.2% against a typical +10.1% from a year earlier.6th of 14
- Profit growth+61.5% against a typical +30.9% from a year earlier.4th of 13
- Share price, 3 months−2.5% against a typical −12.4%.4th of 13
- Size₹ 1,335.6 Cr. market value against a typical ₹ 62.2 Cr. (1st = largest).4th of 13
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A+ by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]A+ | Stable | 22 Sep 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 22 Sep 2026 | Reaffirmed | [ICRA]A+ | — | ICRA | ₹ 56.5 Cr. | |
| 29 Sep 2025 | Reaffirmed | [ICRA]A+ | — | ICRA | ₹ 56.5 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 30 Oct 2026Upcoming | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2026 and other business matters |
| 6 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 30 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 22 Jan 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 17 Oct 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 4 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 23 May 2025 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 186 | 184 | 181 | 208 | 198 | 205 | 190 | 226 | 204 | 209 | 218 | 258 |
| Expenses | 176 | 179 | 169 | 201 | 190 | 197 | 178 | 224 | 198 | 202 | 207 | 243 |
| Operating Profit | 10 | 5 | 12 | 7 | 8 | 8 | 12 | 3 | 5 | 7 | 11 | 15 |
| OPM % | 5% | 2.9% | 7% | 3.3% | 4.2% | 3.8% | 6% | 1.2% | 2.6% | 3.4% | 5% | 6% |
| Other Income | 16 | 16 | 16 | 37 | 18 | 18 | 13 | 18 | 19 | 10 | 21 | 17 |
| Interest | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 22 | 18 | 24 | 41 | 23 | 23 | 22 | 18 | 21 | 14 | 30 | 29 |
| Tax % | 26% | 27% | 25% | 23% | 26% | 26% | 26% | 26% | 4% | 25% | 26% | 26% |
| Net Profit | 16 | 13 | 18 | 32 | 17 | 17 | 16 | 13 | 20 | 11 | 22 | 21 |
| EPS in Rs | 11.33 | 9.12 | 12.93 | 22.35 | 12.17 | 11.84 | 11.43 | 9.2 | 14.43 | 7.45 | 15.4 | 15.06 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 5%
- 5 Years
- 12%
- 3 Years
- 6%
- TTM
- 8%
- 10 Years
- 12%
- 5 Years
- 11%
- 3 Years
- −52%
- TTM
- 14%
- 10 Years
- 1%
- 5 Years
- 10%
- 3 Years
- −3%
- TTM
- —
- 10 Years
- 19%
- 5 Years
- 22%
- 3 Years
- 7%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| TTK Healthcare | ₹ 1,019.00 | ₹ 1,336 Cr. | 18.8x | 1.2x | 6% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- T. T. Raghunathan
- Executive Chairman of the Board
- S. Kalyanaraman
- Chief Executive Officer, Managing Director, Executive Director
- B. V. K. Durga Prasad
- Chief Financial Officer, President - Finance
- Gowry A. Jaishankar
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.